Featured Research

from universities, journals, and other organizations

'Last resort' antibiotics use on the rise, study suggests

Date:
April 4, 2011
Source:
Society for Healthcare Epidemiology of America
Summary:
A study of antibiotic use demonstrates increased use of carbapenems, over the last five years. These drugs are often considered the last treatment option for severe infections with multi-drug resistant pathogens. The increased carbapenem use is alarming because carbapenem-resistant bacteria are becoming more common.

A large, multi-year study of antibiotic use in Veterans Health Administration's acute care facilities demonstrates dramatically increased use of carbapenems, a powerful class of antibiotics, over the last five years. These drugs are often considered the last treatment option for severe infections with multi-drug resistant pathogens. The increased carbapenem use, which has also been described in non-VA facilities in the US, is alarming because carbapenem-resistant bacteria are becoming more common. Overuse of these drugs could weaken their efficacy, threatening their effectiveness against these and other emerging infections.

The study was presented April 3 at the annual meeting of the Society for Healthcare Epidemiology of America (SHEA).

Using barcode medication administration (BCMA) data for antibiotics administered in 110 VA acute care health facilities from 2005-2009, Makoto Jones, MD, and colleagues identified an increasing trend in the use of broad spectrum antibiotics. In the study's five year period, researchers noted a gradual increase in overall antibiotic use, but striking increases in the use of carbapenems (102 percent increase), intravenous vancomycin (79 percent increase), and combinations of penicillin with beta-lactamase-inhibitors (41 percent increase). Fluoroquinolones were the most frequently used drugs across facilities, accounting for 20 percent of all antibiotic use.

"Use of these antibiotics helps the patient receiving the treatment, but has future consequences for innocent bystanders," said Jones. "The more these drugs are used, the more resistance we see." Additionally, the researchers noted that the quantity of antibiotics reported from VA facilities seems to be similar to reported data from non-VA hospitals in the US.

The use of BCMA to collect data of antibiotic use across VA facilities allowed researchers to analyze which antibiotics are given to any patient on any given day. Jones noted that patient-level data permit powerful studies of antibiotic effects that have not been possible to date. Overall, researchers noted that more than half of all patients received at least one dose of any antibiotic during their hospital stay, regardless of presenting condition.

"In this era of multi-drug resistant organisms, clinicians are placed in a difficult situation. As treatment outcomes of many bacterial infections are influenced by the timing of appropriate therapy, the increasing presence of resistant organisms triggers broader use of these powerful antibiotics for proven or suspected infections when treating patients in the hospital" said Steven Gordon, MD, president of SHEA. "Clinicians must always put the patient first in treatment decisions but we must empower effective antibiotic stewardship programs, infection prevention and control efforts, the development of new diagnostic testing to facilitate better treatment decisions as well as support development of new antibiotics"

Among other measures antimicrobial stewardship ensures effective and appropriate use of the medications we have, with a focus on improving patient safety and treatment outcomes while slowing the growth of resistance. Use of individual level data can be used to inform both the basic science and the implementation of antimicrobial stewardship programs.

"Antibiotic use studies in the U.S. are critical to understanding the basic science of how and why resistance is on the rise," said Gordon. "Dr. Jones' study is a clarion call for a need for better diagnostic tools to identify pathogens and resistance as implementation of effective antimicrobial stewardship."


Story Source:

The above story is based on materials provided by Society for Healthcare Epidemiology of America. Note: Materials may be edited for content and length.


Cite This Page:

Society for Healthcare Epidemiology of America. "'Last resort' antibiotics use on the rise, study suggests." ScienceDaily. ScienceDaily, 4 April 2011. <www.sciencedaily.com/releases/2011/04/110403141320.htm>.
Society for Healthcare Epidemiology of America. (2011, April 4). 'Last resort' antibiotics use on the rise, study suggests. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2011/04/110403141320.htm
Society for Healthcare Epidemiology of America. "'Last resort' antibiotics use on the rise, study suggests." ScienceDaily. www.sciencedaily.com/releases/2011/04/110403141320.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins